CASE STUDY

Defensible Scope Reduction in High-Stakes Pharmaceutical IP Litigation

Lineal partnered with a Fortune 100 pharmaceutical company to reduce review scope, cost, and risk in a complex IP litigation — applying governed analytics and Amplify™ Review to eliminate unnecessary first-pass review while preserving defensibility.

CHALLENGE

A Fortune 100 pharmaceutical company faced a large, complex document population requiring rapid review under litigation pressure. Traditional reviewer-heavy first-pass review models risked excessive cost, inconsistent decisions, and delay. The legal team needed to reduce scope dramatically without compromising transparency, defensibility, or confidence in relevance decisions.

OUR APPROACH

Lineal implemented a governed, analytics-led review strategy designed to reduce scope before human review.

- Customized, defensible deduplication to eliminate redundant content
- Amplify™ Review deployed as the primary review workflow
- AI-assisted relevance assessment under Review Manager oversight
- Advanced analytics to identify non-responsive system content
- SME-governed coding with documented decision logic

95%+
Review Volume
Reduced

70%
Post-Amplify™
Reduction

**100%
Defensible
Decisions**

OUTCOME

Lineal reduced review volume by more than 95%, eliminating the need for traditional first-pass review while maintaining full transparency and defensibility. The legal team achieved faster insight, significant cost savings, and greater confidence in review outcomes.

‡ lineal

www.lineal.com